MedCentralNew Lipid Guideline: Start Earlier, Treat LDL More Aggressively

✅ Guideline Update
The 2026 ACC/AHA dyslipidemia guideline, developed with nine collaborating societies, restores LDL-C and non-HDL-C treatment goals abandoned in prior updates and shifts toward “earlier and lower for longer.” It also adds universal one-time lipoprotein(a) measurement for all adults.

Clinical Considerations

• PREVENT equations replace the Pooled Cohort Equations, generating both 10-year and 30-year ASCVD risk estimates for adults aged 30 to 79.
• The “CPR” approach calculates risk, personalizes it with risk enhancers, reclassifies with selective CAC scanning, and reassesses treatment.
• Secondary prevention LDL-C goal is less than 55 mg/dL for very high risk patients; less than 70 mg/dL otherwise; most ASCVD patients will qualify for the lower threshold.
• ApoB testing may refine risk estimates in patients with elevated triglycerides, diabetes, or LDL-C below 70 mg/dL on statin therapy.

Practice Applications

• Integrate PREVENT equations into routine cardiovascular risk assessment.
• Consider lipid-lowering therapy in young adults with LDL-C ≥160 mg/dL or strong family history.
• Monitor LDL-C against age- and risk-stratified goals, including pediatric familial hypercholesterolemia.
• Recognize primary care as the implementation front line for these recommendations.

Related Summaries